Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chindex Ready For China's Healthcare Reform, Competitors

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - Private health care services are finding their niche in China, and Bethesda, Md.-based Chindex is well positioned to withstand future competition and capitalize on China's health care reform

You may also be interested in...



Riding High And Scaling Up, Chindex Readies Business Model Rollout In China

American hospital operator and medical device distributor Chindex is riding strong midterm growth momentum built on its strong branding in China and will likely benefit hugely from China's healthcare reforms and growing middle class.

Riding High And Scaling Up, Chindex Readies Business Model Rollout In China

American hospital operator and medical device distributor Chindex is riding strong midterm growth momentum built on its strong branding in China and will likely benefit hugely from China's healthcare reforms and growing middle class.

American Hospital Operator In China Outlines Blueprints For Broad Expansion In Line With Beijing's Sweeping Health System Reforms

BEIJING - China's sweeping health system reforms, the rise of rich citizenry in its burgeoning mega-cities, and liberalizing government policies are all laying the groundwork for Chindex International to expand its foreign-operated hospitals in the quarters and years ahead, according to the chief executive officer of Chindex

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel